CN113209383B - BMP-2 gene sustained-release coating loaded PEEK composite biological implantation material and preparation method thereof - Google Patents
BMP-2 gene sustained-release coating loaded PEEK composite biological implantation material and preparation method thereof Download PDFInfo
- Publication number
- CN113209383B CN113209383B CN202110532614.4A CN202110532614A CN113209383B CN 113209383 B CN113209383 B CN 113209383B CN 202110532614 A CN202110532614 A CN 202110532614A CN 113209383 B CN113209383 B CN 113209383B
- Authority
- CN
- China
- Prior art keywords
- bmp
- peek
- plga
- test piece
- npeek
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004696 Poly ether ether ketone Substances 0.000 title claims abstract description 65
- 229920002530 polyetherether ketone Polymers 0.000 title claims abstract description 65
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 title claims abstract description 52
- 239000000463 material Substances 0.000 title claims abstract description 46
- 239000011248 coating agent Substances 0.000 title claims abstract description 28
- 238000000576 coating method Methods 0.000 title claims abstract description 28
- 239000002131 composite material Substances 0.000 title claims abstract description 22
- 238000013268 sustained release Methods 0.000 title claims abstract description 17
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000002513 implantation Methods 0.000 title claims abstract description 10
- JUPQTSLXMOCDHR-UHFFFAOYSA-N benzene-1,4-diol;bis(4-fluorophenyl)methanone Chemical compound OC1=CC=C(O)C=C1.C1=CC(F)=CC=C1C(=O)C1=CC=C(F)C=C1 JUPQTSLXMOCDHR-UHFFFAOYSA-N 0.000 title claims abstract 16
- 239000004005 microsphere Substances 0.000 claims abstract description 52
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000007943 implant Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 18
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 15
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 14
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims abstract 7
- 238000012360 testing method Methods 0.000 claims description 58
- 229920001690 polydopamine Polymers 0.000 claims description 35
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- 239000013612 plasmid Substances 0.000 claims description 18
- 108020004414 DNA Proteins 0.000 claims description 16
- 229920002873 Polyethylenimine Polymers 0.000 claims description 16
- 239000008367 deionised water Substances 0.000 claims description 15
- 229910021641 deionized water Inorganic materials 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 14
- 229960003638 dopamine Drugs 0.000 claims description 14
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 11
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 6
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 6
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000007795 chemical reaction product Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 239000000178 monomer Substances 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 3
- 102000012410 DNA Ligases Human genes 0.000 claims description 3
- 108010061982 DNA Ligases Proteins 0.000 claims description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 3
- 241001135569 Human adenovirus 5 Species 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- -1 hydrazine hexaethylene glycol Chemical compound 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 238000005498 polishing Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 229960002317 succinimide Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims 1
- 229920001601 polyetherimide Polymers 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 7
- 238000005538 encapsulation Methods 0.000 abstract description 7
- 238000011068 loading method Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000000839 emulsion Substances 0.000 abstract description 5
- 125000000524 functional group Chemical group 0.000 abstract description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- 230000008468 bone growth Effects 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 3
- 230000011164 ossification Effects 0.000 abstract description 3
- 230000005855 radiation Effects 0.000 abstract description 3
- 238000010517 secondary reaction Methods 0.000 abstract description 3
- 238000013270 controlled release Methods 0.000 abstract description 2
- 239000003102 growth factor Substances 0.000 abstract description 2
- 239000011664 nicotinic acid Substances 0.000 abstract description 2
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 24
- 230000000694 effects Effects 0.000 description 11
- 239000002245 particle Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000010883 osseointegration Methods 0.000 description 4
- 239000012620 biological material Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000009818 osteogenic differentiation Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000009832 plasma treatment Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical group O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- OBOXTJCIIVUZEN-UHFFFAOYSA-N [C].[O] Chemical compound [C].[O] OBOXTJCIIVUZEN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000003364 biologic glue Substances 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010559 graft polymerization reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/622—Microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
Abstract
A PEEK composite biological implantation material loaded with a BMP-2 gene slow release coating and a preparation method thereof, belonging to the technical field of biomedical materials. The invention utilizes a double emulsion solvent volatilization method to prepare PLGA-NH carrying BMP-2 gene2Sustained release microspheres; simultaneously, preparing PEEK with nanometer topological appearance and nitrogen-containing functional groups by adopting a nitrogen low-temperature plasma radiation technology, constructing a PDA bionic coating on the surface of the PEEK by depending on the 'wet bonding characteristic' of the PDA, and grafting PLGA-NH carrying BMP-2 genes by taking the PDA as a secondary reaction platform2The microspheres are slowly released, so that a controlled-release gene slow-release system is constructed on the surface of the PEEK, and the composite biological implant material is obtained. The invention introduces PLGA microspheres as a slow release coating, prolongs the effective release time of the bone growth factor, is matched with the key period of bone defect healing, realizes a stable and long bone formation process, and has higher drug loading rate and encapsulation rate.
Description
Technical Field
The invention belongs to the technical field of biomedical materials, and particularly relates to a polyether-ether-ketone (PEEK) composite biological implant material loaded with a bone morphogenetic protein-2 (BMP-2) gene sustained-release coating and a preparation method thereof.
Background
As a high-performance implant material, Polyetheretherketone (PEEK) and composite materials thereof have excellent performances of good biocompatibility, high strength, high hardness, corrosion resistance, wear resistance, high temperature resistance, similar elastic modulus with bone tissues and the like, and are one of nonmetal bioprosthetic materials with wide application prospects. The PEEK composite material is used as an orthopedic implant and is applied to the fields of spinal surgery, joint surgery, wound repair and the like, and a good repair effect is achieved. However, PEEK is a bio-inert material, and its hydrophobic surface and high reaction inertia result in low surface energy, poor biological activity, and difficulty in obtaining a very desirable osseointegration effect after being implanted into a human body. If the biological activity of PEEK can be obviously improved on the premise of not influencing the mechanical property of the body, the osseointegration effect of PEEK can be expected to be improved, and a novel medical implant material with more excellent performance is developed.
With the cross-infiltration development of subjects such as materials science, scale chemistry, modern life science and the like, and the continuous breakthrough of relevant theories and technologies such as cell biology, molecular biology and the like, a target gene with the effect of promoting bone is loaded on the surface of an implant material, the interaction between the target gene and cells of an implanted area is accurately regulated and controlled from the gene level, the faster osseous integration (osseointegration) of an implant body and bone tissues is realized, and a brand new thought is provided for the effective modification of the surface of the implant material. A great deal of literature has proved that BMP-2 protein coded by BMP-2 gene can positively regulate the regeneration and repair process of bone tissue, and is a key action factor for forming osseointegration between implant and bone tissue in the implanted area. Therefore, a BMP-2 gene slow release system is constructed on the surface of the PEEK implant material, so that the BMP-2 gene is further transfected into bone mesenchymal stem cells of peripheral tissues of an implant, the secretion of therapeutic BMP-2 protein beneficial to osteogenesis is promoted, the effect of promoting the regeneration of bone tissues is continuously exerted, and the method is a feasible way for improving the biological activity of the PEEK.
Polydopamine (PDA) is formed by Dopamine (DA) which is in contact with air under the condition of alkalescence and automatically generates oxidative polymerization, is rich in catechol groups and amino functional groups of lysine, and has super-strong adhesion property. The PDA has good biocompatibility, is a biological adhesive with great advantages and potentials, can be adhered to the surfaces of almost all materials, including organic, inorganic and biological materials, and forms a functionalized nano thin layer on the surface of the material. Because the o-phenol group contained in PDA is very easy to be oxidized into cyclohexadienedione structure, the structure can be combined with the compound containing amino (-NH)2) And sulfhydryl (-SH) or imino (-NH-) organic polymer to generate Schiff base or Michael addition reaction to form stable chemical bonding force, and lay the foundation for grafting sulfhydrylation or amination bioactive molecules and realizing functional modification of biological materials. Therefore, by using PDA as a secondary reaction platform, it is possible to firmly combine the sulfhydrylation or amination bioactive molecules on the surface of the biomaterial through graft polymerization, thereby changing the microenvironment of the bone implant material and significantly improving the bone combination effect.
Disclosure of Invention
The invention aims to provide a polyether ether ketone (PEEK) composite biological implant material loaded with a bone morphogenetic protein-2 (BMP-2) gene sustained-release coating and a preparation method thereof.
The invention aims to construct an osteogenic slow-release coating on the surface of PEEK, and firstly utilizes a double emulsion solvent volatilization method to prepare PLGA-NH carrying BMP-2 gene2Sustained release microspheres (PLGA: polylactic-co-glycolic acid); simultaneously, preparing PEEK with nanometer topological appearance and nitrogen-containing functional groups by adopting a nitrogen low-temperature plasma radiation technology, constructing a PDA bionic coating on the surface of the PEEK by depending on the 'wet bonding characteristic' of the PDA, and grafting PLGA-NH carrying BMP-2 genes by taking the PDA as a secondary reaction platform2The sustained release microspheres are used for constructing a controlled release gene sustained release system on the surface of PEEK, thus obtaining the inventionThe polyether-ether-ketone (PEEK) composite biological implant material loaded with the bone morphogenetic protein-2 (BMP-2) gene slow release coating.
The invention relates to a preparation method of a PEEK composite biological implantation material loaded with a BMP-2 gene slow release coating, which comprises the following steps as shown in figure 7:
1) dissolving 4-6 g of PLGA containing free carboxyl terminal into 40-60 mL of dichloromethane, adding 40-50 mg of dicyclohexylcarbodiimide and 25-26 mg of N-succinimide, stirring for 11-13 h, separating a reaction product from a precipitate in anhydrous ether, and drying in vacuum to obtain carboxyl activated PLGA;
2) Adding 370-380 mg of hydrazine hexaethylene glycol and carboxyl activated PLGA obtained in the step 1) into 40-60 mL of anhydrous DMSO, stirring for 11-13 h, adding a reaction product into 0-4 ℃ of anhydrous ethanol, separating and precipitating, and drying in vacuum to obtain the aminated PLGA slow release microspheres marked as PLGA-NH2Sustained release microspheres;
3) mixing the following components in a mass ratio of 1: 1, mixing BMP-2 plasmid and Polyethyleneimine (PEI), adding deionized water to prepare a PEI/DNA complex aqueous solution, wherein the concentration of the BMP-2 plasmid in the complex aqueous solution is 50-70 mu g/mL;
4) adding 0.4-0.6 mL of PEI/DNA compound aqueous solution obtained in the step 3) into 1-3 mL of PLGA-NH with the mass fraction of 2%2In a dichloromethane solution of the sustained-release microspheres, stirring for 7-10 s under the condition of 4000-5000 rpm in an ice bath, then quickly pouring into 8-10 mL of polyvinyl alcohol (PVA) aqueous solution with the mass fraction of 3%, stirring for 5-10 s under the condition of 8000-10000 rpm, then pouring into 15-25 mL of polyvinyl alcohol (PVA) aqueous solution with the mass fraction of 0.5%, stirring for 2-4 h, then centrifuging for 10-15 min under the condition of 4000-6000 rpm, washing and precipitating for 2-4 times by deionized water, and then freeze-drying the precipitate to obtain PLGA-NH carrying BMP-2 gene2Slow-release microspheres, denoted PLGA-NH2@ pBMP-2 microspheres, stored at 4 ℃;
5) Grinding and polishing a PEEK test piece (phi is 10mm, and delta is 1mm), sequentially ultrasonically cleaning the PEEK test piece for 20-40 min by using acetone, absolute ethyl alcohol and deionized water, drying the PEEK test piece, and treating the surface of the PEEK test piece for 10-15 min by using nitrogen low-temperature plasma under the conditions of 400-500V voltage, 400-600W power and 10-20 Pa pressure to obtain a test piece NPEEK;
6) dissolving Dopamine (DA) in 10mmol/L Tris-HCl buffer solution to prepare a dopamine solution with the pH value of 8.5 and the concentration of 2 g/L; soaking the test piece NPEEK obtained in the step 5) in the test piece NPEEK, placing the test piece NPEEK in a constant-temperature shaking table at 37 ℃, taking out the test piece NPEEK after the light-shielding reaction is carried out for 20-24 hours, and repeatedly washing the test piece NPEEK by using deionized water to obtain a test piece NPEEK with Polydopamine (PDA) deposited on the surface, and marking the test piece NPEEK-PDA as a test piece NPEEK-PDA;
7) taking 80-100 mg of PLGA-NH obtained in the step 4)2Mixing the @ pBMP-2 microspheres in 10mL of deionized water uniformly to prepare a high-concentration suspension of the microspheres; placing the test piece NPEEK-PDA obtained in the step 6) in a high-concentration suspension of microspheres for reacting for 4-6 h, and freeze-drying to obtain the test piece with PLGA-NH loaded on the surface2NPEEK-PDA test piece of microsphere, mark as NPEEK-PDA- (PLGA-NH)2@ pBMP-2), namely the PEEK composite biological implantation material loaded with the BMP-2 gene sustained release coating.
In the method, the molar ratio of the lactic acid monomer to the glycolic acid monomer in the PLGA in the step 1) is 50: 50, Mw 10000;
Step 3) firstly, digesting pCMV6-XL4 by Not I, then treating the digestion product by T4 DNA polymerase, and then digesting the digestion product by Eco RI to obtain a linear DNA fragment containing a BMP-2 target gene, wherein the DNA fragment has a cohesive end and a flat end at the same time; digesting the pACCMV-plpA shuttle plasmid of adenovirus type 5 by BamH I, flattening the viscous end by T4 DNA polymerase, digesting by Eco RI, and connecting the digested plasmid with a DNA fragment containing a BMP-2 target gene by using DNA ligase to obtain a BMP-2 plasmid (pBMP-2 for short); mw of PEI 25,000;
and step 5), the plasma generator is a nitrogen plasma reactor, the reaction pressure is 20pa, the voltage is 500V, the power is 500W, and the time is 15 min.
Step 6) the pH of the dopamine solution was adjusted using sodium hydroxide (0.1 mol/L).
Compared with the prior art, the invention has the following advantages:
(1) PLGA-NH prepared by multiple emulsion solvent volatilization method2The @ pBMP-2 microspheres and the W/O/W type multiple emulsion can effectively prevent the water-soluble medicine from entering a continuous phase so as to improve the encapsulation efficiency;
(2) the PEI nano particles with positive charges and the BMP-2 plasmids with negative charges are used for electrostatic attraction, the maximal aggregation of the plasmids is realized, the encapsulation efficiency is improved, and on the other hand, the formed compound protects the BMP-2 plasmids from being damaged in the preparation process of the microspheres.
(3) The nitrogen low-temperature plasma radiation is convenient to operate and has obvious effect. When the particles with high energy impact the material, the original appearance can be damaged, an uneven nano-scale structure is formed, and the surface area of the substrate material is increased; meanwhile, macromolecular chains on the surface of the substrate material are broken and bonded with active particles in plasma or active gas molecules in air, and new elements and functional groups are introduced on the surface, which are both beneficial to the deposition of PDA and the biological related activity of the surface of the material.
(4) The PDA coating is introduced, not only the chemical bonding factor of the fixed microspheres is considered, but also the good cell biological activity of the PDA coating is considered, the calcium ion deposition can be promoted, and the osteogenic differentiation of cells can be induced;
(5) three surface modification strategies of nano-matrix composite material preparation, plasma surface modification and gene-loaded sustained-release microsphere preparation are comprehensively applied to achieve a composite effect, and the method belongs to cross innovation research in the fields of materials science, supermolecule chemistry and medicine.
The preparation method of the invention obtains the PEEK biological implantation material loaded with the BMP-2 gene slow release coating, the surface successfully constructs the nano topological morphology, and the microspheres are uniformly dispersed on the surface of the substrate material; the microspheres synthesized by the multiple emulsion solvent volatilization method have uniform particle size, complete form and higher drug loading rate and encapsulation rate. The release of BMP-2 plasmid of the whole material is relatively stable within 40 days, and the accumulated release amount reaches 82%. As is well known, BMP-2 is the most potential bone growth stimulating factor in the bone morphogenetic protein family, can induce mesenchymal stem cells to differentiate into osteoblasts, thereby promoting the healing and repair of bone defects, and the effect can make up the biological inertia of PEEK materials. PLGA microspheres are introduced as a slow release coating, so that the effective release time of the bone growth factor is prolonged, the effective release time is matched with the key period of bone defect healing, and a stable and long-term bone formation process is realized. The surface appearance, functional groups, roughness and hydrophilicity of the material are improved, and a high-quality environment is provided for cell adhesion and osteogenic differentiation.
Drawings
FIG. 1 shows PLGA-NH obtained in step 4) of example 12The particle size distribution of the microspheres, wherein the inset is a scanning electron microscope picture of the microspheres.
It can be seen that PLGA-NH2The microspheres are regular spheres, full in shape, smooth in surface and almost free of damage or adhesion. The particle sizes of the microspheres are basically uniform, and 90% of the particle sizes of the microspheres are found to be distributed in the range of 0.8-5.6 microns after a plurality of SEM pictures are selected and subjected to the statistical analysis of Nano measurer 1.2. The content of unencapsulated DNA in the microsphere supernatant is measured by a double-stranded DNA quantitative detection kit and a fluorescence microplate reader, and the drug loading capacity and the encapsulation efficiency are further evaluated. The drug loading rate and the encapsulation rate are respectively calculated according to the following formulas:
PLGA-NH synthesized by the method2The drug loading rate and the encapsulation rate of the microspheres are respectively 1.6% + -0.6% and 42.7% + -6.9%.
FIGS. 2A, 2B, 2C, and 2D are test pieces of PEEK, NPEEK-PDA, and NPEEK-PDA- (PLGA-NH), respectively2@ pBMP-2) surface microtopography.
Therefore, the surface of the untreated PEEK test piece is relatively flat and smooth, and grinding traces can be seen. Strip-shaped irregular bulges are formed on the surface of a PEEK test piece (NPEEK) subjected to nitrogen low-temperature plasma treatment, and each bulge surface is composed of a plurality of small bulges which are closely arranged. After dopamine is deposited on the surface of a test piece (NPEEK-PDA), the original convex-concave appearance becomes unobvious and only shows a strip-shaped structure. After microspheres are loaded (NPEEK-PDA- (PLGA-NH) 2@ pBMP-2)), it can be seen that the microspheres are successfully dispersed on the surface of the base material, most of the microspheres can still maintain the full spherical state, and onlyA small fraction of them are broken during the microsphere immobilization process.
FIGS. 3A, 3B, 3C, 3D and Table 1 show test pieces PEEK, NPEEK-PDA and NPEEK-PDA- (PLGA-NH), respectively2@ pBMP-2) and roughness data.
TABLE 1 test pieces PEEK, NPEEK-PDA- (PLGA-NH)2@ pBMP-2) roughness data (Ra for mean, RMS for root mean Square value)
It can be seen that pure PEEK has a smooth surface with minimal roughness compared to the other groups. The NPEEK surface is generally formed with volcano-like elevations and is doped with many small protrusions, and the roughness is significantly increased due to the large surface relief. Granular protrusions with dopamine aggregation can be seen on the surface of NPEEK-PDA, and the roughness is slightly reduced. As the maximum particle size of the microspheres can reach about 5.6 mu m, AFM can only represent NPEEK-PDA- (PLGA-NH)2@ pBMP-2), this group having the greatest roughness.
FIGS. 4A, 4B, 4C and Table 2 show the element characterization curves and assay data of the test pieces PEEK, NPEEK and NPEEK-PDA, respectively.
It can be seen that PEEK is composed of C and O elements, and therefore there are corresponding characteristic peaks at 284.6eV and 532.5 eV. After the PEEK was treated with nitrogen low-temperature plasma, a large amount of nitrogen-containing elements were grafted, and thus NPEEK showed a characteristic peak of nitrogen at 400eV, while detecting a nitrogen content of 4.42%. After PDA modification, C, O, N element peak is detected on the surface of the test piece, the nitrogen content is changed to 6.98%, and it is noted that the NPEEK-PDA group is very similar to the theoretical ratio of corresponding dopamine content no matter the oxygen-carbon content ratio or the nitrogen-carbon content ratio, so that the PDA coating is successfully formed on the surface of the test piece.
Table 2: element content data of test pieces PEEK, NPEEK and NPEEK-PDA
| Grouping | C(％) | O(％) | N(％) | O/C | N/C |
| PEEK | 76.96 | 21.23 | - | 0.276 | - |
| NPEEK | 63.12 | 23.69 | 4.42 | 0.375 | 0.07 |
| NPEEK-PDA | 73.88 | 19.14 | 6.98 | 0.259 | 0.945 |
FIG. 5 shows test pieces of PEEK, NPEEK-PDA- (PLGA-NH)2@ pBMP-2).
It can be seen that the PEEK without any treatment has the largest contact angle, about 83.1 °, which is hydrophobic relative to the other groups. After plasma treatment, NPEEK became hydrophilic and the contact angle decreased to 58.2 °. After coating on PDA, the contact angle of the material surface is further reduced, making the material have excellent hydrophilicity. Whereas the water contact angle increased slightly to 47.1 ° after addition of the microspheres to NPEEK-PDA, mainly due to micron-scale topography hindering the diffusion of water molecules.
FIG. 6 is a graph showing the effect of NPEEK-PDA- (PLGA-NH2@ pBMP-2) on sustained release.
Therefore, the pBMP-2 is released at a high speed in the first 7 days, and the release of the pBMP-2 is accelerated after the microspheres are fixed due to the inevitable dissolution reaction in the process of loading part of the microspheres on the surface of the PEEK test piece. After 7 days, the release rate of the pBMP-2 is gradually slowed down, finally the pBMP-2 is released more stably within 40 days, the cumulative release amount reaches 82 percent, and the aim of releasing the pBMP-2 for a long time by the material is fulfilled.
FIG. 7 is a synthetic flow chart of a PEEK biological implantation material loaded with a BMP-2 gene slow release coating.
Detailed Description
Example 1:
1) 5g of PLGA containing free carboxyl ends (wherein the molar ratio of lactic acid to glycolic acid monomers was 50: 50, Mw 10000) is dissolved in 50mL of dichloromethane, then 45.4mg of dicyclohexylcarbodiimide and 25.3mg of N-succinimide are added, after stirring for 12 hours, the reaction product is separated from the precipitate in anhydrous ether, and after vacuum drying, carboxyl activated PLGA is obtained;
2) adding 375mg of hydrazine hexaethylene glycol and carboxyl activated PLGA obtained in the step 1) into 50mL of anhydrous DMSO, stirring for 12h, adding a reaction product into anhydrous ethanol at 4 ℃, separating precipitates, and drying in vacuum to obtain the aminated PLGA slow release microspheres marked as PLGA-NH2Sustained release microspheres;
3) digesting pCMV6-XL4 by Not I, treating the digested pCMV6-XL4 by T4 DNA polymerase, and digesting the digested pCMV6-XL4 by Eco RI to obtain a linear DNA fragment containing a BMP-2 target gene, wherein the fragment has a cohesive end and a blunt end at the same time; digesting the pACCMV-plpA shuttle plasmid of adenovirus type 5 by BamH I, flattening the viscous end by T4 DNA polymerase, digesting by Eco RI, and connecting the digested plasmid with a DNA fragment containing a BMP-2 target gene by using DNA ligase to obtain a BMP-2 plasmid (pBMP-2 for short); the mass ratio of BMP-2 plasmid to Polyethyleneimine (PEI) is 1: 1, preparing 0.6mL PEI/DNA complex aqueous solution containing 36 mu g BMP-2 plasmid by using deionized water;
4) 0.6mL of PEI/DNA complex aqueous solution obtained in the step 3) is added into 2mL of PLGA-NH with the mass fraction of 2%2In dichloromethane solution of slow-release microspheres, stirring for 10s under ice bath and 5000rpm, quickly pouring into 10mL of polyvinyl alcohol (PVA) aqueous solution with the mass fraction of 3%, stirring for 10s under 10000rpm, then pouring into 20mL of PVA aqueous solution with the mass fraction of 0.5%, stirring for 4h, centrifuging for 15min under 5000rpm, washing and precipitating with deionized water for 3 times, and freeze-drying the precipitate to obtain PLGA-NH2@ pBMP-2 microsphere powder, storing at 4 deg.C;
5) grinding and polishing a PEEK test piece (phi is 10mm, and delta is 1mm), sequentially ultrasonically cleaning the PEEK test piece for 30min by using acetone, absolute ethyl alcohol and deionized water, drying the PEEK test piece, placing the PEEK test piece into a plasma processor, and treating the surface of the PEEK test piece for 15min by using nitrogen low-temperature plasma under the conditions of 500V voltage, 500W power and 20Pa pressure to obtain a test piece NPEEK;
6) dissolving DA in 10mmol/L Tris-HCl buffer solution to prepare a dopamine solution with the pH value of 8.5 and the concentration of 2 g/L; soaking the test piece NPEEK obtained in the step 5) in the test piece NPEEK, placing the test piece NPEEK in a constant-temperature shaking table at 37 ℃, taking out the test piece NPEEK after the light-shielding reaction is carried out for 24 hours, and repeatedly washing the test piece NPEEK by using deionized water to obtain the test piece NPEEK with the surface deposited with Polydopamine (PDA), and marking the test piece NPEEK as NPEEK-PDA;
7) Taking 100mg of PLGA-NH obtained in the step 4)2Mixing the @ pBMP-2 microspheres in 10mL of deionized water uniformly to prepare a high-concentration suspension of the microspheres; placing the test piece NPEEK-PDA obtained in the step 6) in the prepared microsphere suspension for reacting for 6h, and freeze-drying to obtain the test piece with the surface loaded with PLGA-NH2NPEEK-PDA test piece of microsphere, mark as NPEEK-PDA- (PLGA-NH)2@ pBMP-2), namely the PEEK composite biological implantation material loaded with the BMP-2 gene sustained release coating.
Claims (7)
1. A preparation method of a PEEK composite biological implantation material loaded with a BMP-2 gene slow release coating comprises the following steps:
1) dissolving 4-6 g of PLGA containing free carboxyl terminal into 40-60 mL of dichloromethane, adding 40-50 mg of dicyclohexylcarbodiimide and 25-26 mg of N-succinimide, stirring for 11-13 h, separating a reaction product from a precipitate in anhydrous ether, and drying in vacuum to obtain carboxyl activated PLGA;
2) adding 370-380 mg of hydrazine hexaethylene glycol and carboxyl activated PLGA obtained in the step 1) into 40-60 mL of anhydrous DMSO, stirring for 11-13 h, adding a reaction product into 0-4 ℃ of anhydrous ethanol, separating and precipitating, and drying in vacuum to obtain the aminated PLGA slow release microspheres marked as PLGA-NH2Sustained release microspheres;
3) mixing the following components in a mass ratio of 1: 1, mixing BMP-2 plasmid and PEI, adding deionized water to prepare a PEI/DNA complex aqueous solution, wherein the concentration of the BMP-2 plasmid in the complex aqueous solution is 50-70 mu g/mL;
4) Adding 0.4-0.6 mL of PEI/DNA compound aqueous solution obtained in the step 3) into 1-3 mL of PLGA-NH with the mass fraction of 2%2In a dichloromethane solution of the sustained-release microspheres, stirring for 7-10 s under the condition of ice bath and 4000-5000 rpm, then quickly pouring into 8-10 mL of PVA aqueous solution with the mass fraction of 3%, stirring for 5-10 s under the condition of 8000-10000 rpm, then pouring into 15-25 mL of PVA aqueous solution with the mass fraction of 0.5%, stirring for 2-4 h, centrifuging for 10-15 min under the condition of 4000-6000 rpm, washing and precipitating with deionized water for 2-4 times, and freeze-drying the precipitate to obtain PLGA-NH-carrying BMP-2 gene2Slow-release microspheres, denoted PLGA-NH2@ pBMP-2 microsphere powder, storing at 4 deg.C;
5) polishing a PEEK test piece, sequentially ultrasonically cleaning the PEEK test piece for 20-40 min by using acetone, absolute ethyl alcohol and deionized water, drying the PEEK test piece, and treating the surface of the PEEK test piece for 10-15 min by using nitrogen low-temperature plasma under the conditions of 400-500V voltage, 400-600W power and 10-20 Pa pressure to obtain a test piece NPEEK;
6) dissolving dopamine in a Tris-HCl buffer solution of 10mmol/L to prepare a dopamine solution with the pH value of 8.5 and the concentration of 2 g/L; soaking the test piece NPEEK obtained in the step 5) in the test piece NPEEK, placing the test piece NPEEK in a constant-temperature shaking table at 37 ℃, taking out the test piece NPEEK after the light-shielding reaction is carried out for 20-24 hours, and repeatedly washing the test piece NPEEK by using deionized water to obtain the test piece NPEEK with polydopamine deposited on the surface, and marking the test piece NPEEK-PDA as a test piece NPEEK-PDA;
7) Taking 80-100 mg of PLGA-NH obtained in the step 4)2Mixing the @ pBMP-2 microspheres in 10mL of deionized water uniformly to prepare a high-concentration suspension of the microspheres; placing the test piece NPEEK-PDA obtained in the step 6) in a high-concentration suspension of microspheres for reacting for 4-6 h, and freeze-drying to obtain a PEEK composite biological implant material loaded with a BMP-2 gene slow release coating; wherein, PLGA is polylactic acid-glycolic acid copolymer, PEEK is polyether ether ketone, PEI is polyethyleneimine, PVA is polyvinyl alcohol.
2. The method for preparing the PEEK composite biological implant material loaded with the BMP-2 gene slow-release coating of claim 1, wherein the preparation method comprises the following steps: step 1), in PLGA, the molar ratio of lactic acid monomer to glycolic acid monomer is 50: 50, Mw 10000.
3. The method for preparing the PEEK composite biological implant material loaded with the BMP-2 gene slow-release coating of claim 1, wherein the preparation method comprises the following steps: in the step 3), firstly, after the pCMV6-XL4 is digested by Not I, the digestion is carried out by T4 DNA polymerase, and then the digestion is carried out by Eco RI to obtain a linear DNA fragment containing a BMP-2 target gene, wherein the DNA fragment has a cohesive end and a flat end at the same time; then digesting the pACCMV-plpA shuttle plasmid of adenovirus type 5 by BamH I, then flattening the viscous end by T4 DNA polymerase, digesting by Eco RI, and connecting the DNA fragment containing the BMP-2 target gene by using DNA ligase to obtain the BMP-2 plasmid.
4. The method for preparing the PEEK composite biological implant material loaded with the BMP-2 gene slow-release coating of claim 1, wherein the preparation method comprises the following steps: in step 3), Mw of PEI was 25,000.
5. The method for preparing the PEEK composite biological implant material loaded with the BMP-2 gene slow-release coating of claim 1, wherein the preparation method comprises the following steps: and 5) treating the nitrogen plasma at the pressure of 20pa, the voltage of 500V, the power of 500W and the time of 15 min.
6. The method for preparing the PEEK composite biological implant material loaded with the BMP-2 gene slow-release coating of claim 1, wherein the preparation method comprises the following steps: step 6) the pH of the dopamine solution is adjusted with 0.1mol/L sodium hydroxide.
7. A PEEK composite biological implantation material loaded with a BMP-2 gene slow release coating is characterized in that: is prepared by the method of any one of claims 1 to 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110532614.4A CN113209383B (en) | 2021-05-17 | 2021-05-17 | BMP-2 gene sustained-release coating loaded PEEK composite biological implantation material and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110532614.4A CN113209383B (en) | 2021-05-17 | 2021-05-17 | BMP-2 gene sustained-release coating loaded PEEK composite biological implantation material and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113209383A CN113209383A (en) | 2021-08-06 |
| CN113209383B true CN113209383B (en) | 2022-01-11 |
Family
ID=77092200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110532614.4A Expired - Fee Related CN113209383B (en) | 2021-05-17 | 2021-05-17 | BMP-2 gene sustained-release coating loaded PEEK composite biological implantation material and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113209383B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114558170B (en) * | 2022-01-24 | 2023-04-25 | 武汉亚洲生物材料有限公司 | Growth factor-containing skull repair polyether-ether-ketone material and preparation method thereof |
| CN114699551B (en) * | 2022-02-24 | 2023-05-16 | 武汉亚洲生物材料有限公司 | Preparation method and application of surface composite coating titanium mesh |
| CN114887117B (en) * | 2022-04-09 | 2023-10-13 | 中国医科大学附属第一医院 | Drug-loaded nanoparticle and vascular stent for reducing restenosis rate in blood vessel after operation |
| CN115025723A (en) * | 2022-05-10 | 2022-09-09 | 吉林大学 | PEG-PLGA microspheres modified by nerve growth factor and dopamine |
| CN115282335B (en) * | 2022-08-05 | 2023-08-29 | 河北医科大学口腔医院 | Preparation method of bone repair stent |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011059123A1 (en) * | 2009-11-11 | 2011-05-19 | 주식회사 메디프렉스 | Heparin compound bound to adhesive material, preparation method thereof, solid surface coating agent containing same as active ingredient, and coating method of solid surface using same |
| CN103520783A (en) * | 2008-12-31 | 2014-01-22 | 凯希特许有限公司 | Systems for providing fluid flow to tissues |
| FR3002536A1 (en) * | 2013-02-25 | 2014-08-29 | Inst Polytechnique Grenoble | Use of peptide having alpha helix conformation and assuming monolayer of material e.g. metal oxides having positively/negatively charged hydrophilic surface, to inhibit aggregation of e.g. soluble calcitonin in contact with the surface |
| CN107224621A (en) * | 2016-03-23 | 2017-10-03 | 成都交大麦迪克科技有限公司 | One kind has endothelium bionic function coating and preparation method thereof |
-
2021
- 2021-05-17 CN CN202110532614.4A patent/CN113209383B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520783A (en) * | 2008-12-31 | 2014-01-22 | 凯希特许有限公司 | Systems for providing fluid flow to tissues |
| WO2011059123A1 (en) * | 2009-11-11 | 2011-05-19 | 주식회사 메디프렉스 | Heparin compound bound to adhesive material, preparation method thereof, solid surface coating agent containing same as active ingredient, and coating method of solid surface using same |
| FR3002536A1 (en) * | 2013-02-25 | 2014-08-29 | Inst Polytechnique Grenoble | Use of peptide having alpha helix conformation and assuming monolayer of material e.g. metal oxides having positively/negatively charged hydrophilic surface, to inhibit aggregation of e.g. soluble calcitonin in contact with the surface |
| CN107224621A (en) * | 2016-03-23 | 2017-10-03 | 成都交大麦迪克科技有限公司 | One kind has endothelium bionic function coating and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| Current applications of poly(lactic acid) composites in tissue engineering and drug delivery;Shan Liu, Shuhao Qin, Min He et al;《Composites PartB》;20200728;第199卷(第2020期);全文 * |
| 增材制造可降解人工骨的研究进展――从外形定制到性能定制;邵惠锋等;《浙江大学学报(工学版)》;20180620;第52卷(第06期);全文 * |
| 聚醚醚酮在骨移植中的应用;马静等;《化学进展》;20181124;第30卷(第11期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113209383A (en) | 2021-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113209383B (en) | BMP-2 gene sustained-release coating loaded PEEK composite biological implantation material and preparation method thereof | |
| Wang et al. | Chitosan/gelatin porous scaffolds assembled with conductive poly (3, 4-ethylenedioxythiophene) nanoparticles for neural tissue engineering | |
| Joshi et al. | Applications of dendrimers in tissue engineering | |
| Gao et al. | Polydopamine-templated hydroxyapatite reinforced polycaprolactone composite nanofibers with enhanced cytocompatibility and osteogenesis for bone tissue engineering | |
| Han et al. | Mussel-inspired graphene oxide nanosheet-enwrapped Ti scaffolds with drug-encapsulated gelatin microspheres for bone regeneration | |
| Yuan et al. | Immobilization of gelatin onto poly (glycidyl methacrylate)-grafted polycaprolactone substrates for improved cell–material interactions | |
| Lee et al. | Hydroxyapatite-containing gelatin/chitosan microspheres for controlled release of lysozyme and enhanced cytocompatibility | |
| CN100531807C (en) | Polylactic acid base/nano hydroxyapatite biological material and preparation method thereof | |
| WO2000041647A1 (en) | Sustained delivery of polyionic bioactive agents | |
| CN108721704B (en) | Long-acting sustained-release cardiovascular coating material with dual functions of calcification resistance and hyperplasia resistance and preparation method thereof | |
| Song et al. | Room-temperature fabrication of a three-dimensional reduced-graphene oxide/polypyrrole/hydroxyapatite composite scaffold for bone tissue engineering | |
| Motiee et al. | Investigation of physical, mechanical and biological properties of polyhydroxybutyrate-chitosan/graphene oxide nanocomposite scaffolds for bone tissue engineering applications | |
| US20160346218A1 (en) | Hybrid hollow microcapsule, scaffold for soft tissue including same, and methods of preparing same | |
| WO2022012339A1 (en) | Method for constructing bone morphogenetic protein sustained-release system | |
| CN107260706A (en) | Double medicament-carried nano carriers of a kind of cancer target and preparation method thereof | |
| CN105327364B (en) | A kind of nanometer hydroxyapatite-siRNA compound and preparation method thereof | |
| Amiryaghoubi et al. | Recent advances in graphene-based polymer composite scaffolds for bone/cartilage tissue engineering | |
| Song et al. | Constructing a biomimetic nanocomposite with the in situ deposition of spherical hydroxyapatite nanoparticles to induce bone regeneration | |
| Aghajanzadeh et al. | Augmented physical, mechanical, and cellular responsiveness of gelatin-aldehyde modified xanthan hydrogel through incorporation of silicon nanoparticles for bone tissue engineering | |
| Xu et al. | Osteogenic and anti-inflammatory effects of SLA titanium substrates doped with chitosan-stabilized selenium nanoparticles via a covalent coupling strategy | |
| Gulati et al. | In situ transformation of chitosan films into microtubular structures on the surface of nanoengineered titanium implants | |
| Gendelberg et al. | Nanocomposites for biomedical applications | |
| Keaswejjareansuk et al. | Degradable alginate hydrogel microfiber for cell-encapsulation based on alginate lyase loaded nanoparticles | |
| Lin et al. | Enhancing bone regeneration with bionic hydrolysis and biomimetic polydopamine coating on 3D-printed PCL scaffolds: a comparative study | |
| Wang et al. | The effect of magnetic poly (lactic-co-glycolic acid) microsphere-gelatin hydrogel on the growth of pre-osteoblasts under static magnetic field |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220111 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |